As at September 2020, a total captured of...

7496 projects
141 funders
5.6bn USD

Geographical coverage of investments

34 countries + EU
5 continents
28% investment at international level

Most funding is directed towards...

30% basic research
41% product-related R&D
22% support for operational and implementation research
Pipeline of human antibacterials in clinical development

Remains fragile, with low numbers and relatively weak innovativeness and with only about two fifths of the compounds in development or recently approved addressing some of the most critical pathogens.

Incentives for antibacterial R&D

Late-stage push incentives for the later, more expensive stages of therapeutic development, concentrated in a few funders.

Pull incentives remain *ad hoc*, small-scale and initiated by just a few countries globally.

Conclusion and next steps

First consolidation of national AMR-related R&D funding

Report provides a baseline, representing two full years of data (2017 and 2018).

The outcomes and resulting analysis will help to identify opportunities and gaps in AMR R&D and inform about progress in the AMR R&D field.